Compounded Semaglutide In 2026: What Changed, What's Next

The boom years: 2022–2024

From approximately late 2022 through early 2025, semaglutide was on the FDA Drug Shortage List. This matters because of a specific legal provision: 503A and 503B compounding pharmacies can legally produce compounded versions of drugs listed in shortage.

During these ~2.5 years:

• Major compounding pharmacies scaled semaglutide production massively
• Telehealth services (Hims, Ro, Henry Meds, etc.) built substantial businesses on compounded semaglutide
• Cash prices dropped from $1,300+/month (branded Wegovy) to $200–400/month (compounded)
• Hundreds of thousands of patients accessed GLP-1 therapy through this channel

This was the only time in pharmaceutical history that a major branded drug had a viable cheaper compounded alternative at scale — enabled entirely by the shortage exception.

The 2025 shift

In February 2025, the FDA declared the semaglutide shortage resolved for most strengths. Novo Nordisk had expanded production substantially, and commercial supply of Wegovy and Ozempic had normalized.

This triggered automatic legal consequences:

Subsequent FDA warning letters made clear: continuing to produce compounded semaglutide after the shortage resolution would trigger enforcement action.

The legal pushback

Outsourcing Facilities Association (OFA) and Alliance for Pharmacy Compounding (APC) — trade groups representing compounding pharmacies — filed lawsuits in 2024 and 2025 challenging the FDA's shortage declaration.

The arguments:

1. FDA's shortage declaration was premature
2. Market shortages still existed in certain regions and formulations
3. Patients would be harmed by loss of compounded access
4. Administrative procedure violations

As of April 2026, most of these legal challenges have been rejected or remain in limbo. A few specific carve-outs have been negotiated — particularly around pediatric dosing and certain strength variations — but the mass compounding of semaglutide at commercial scale has largely ended.

What's still legal

503A compounding for specific patients: A pharmacist can compound a formulation specifically for an individual patient with a prescription if:

• The prescriber identifies a specific clinical need not met by commercial products
• The compounded formulation differs meaningfully from the commercial product (e.g., different strength, removing an allergen)
• It's not done as a mass-market activity

This is a narrow exception. It doesn't support the Hims-style business model.

503B outsourcing for specific shortages or unusual demand patterns: Very limited circumstances where shortage conditions return or specific populations can't access branded products.

Research chemical suppliers: Selling semaglutide as a "research chemical" for "research use only" is a separate legal channel. These suppliers operate in legal gray zones — sometimes complying with requirements, sometimes not. Quality varies wildly.

The real-world outcome

For patients who were on compounded semaglutide in 2024:

1. Many have successfully transitioned to branded Wegovy or Ozempic — often via insurance or manufacturer patient assistance programs
2. Some have paid the price difference out of pocket — averaging $1,000+/month more than compounded
3. Some have discontinued treatment due to cost barriers
4. Some have moved to research-chemical sources — with attendant quality risks
5. Some have switched to tirzepatide (which went through a similar cycle but was removed from shortage earlier)

For telehealth services:

• Hims/Hers pivoted to branded products and lower-volume compounding
• Ro similarly adapted
• Dedicated weight-loss services had varying outcomes — some went under
• New services emerged around tirzepatide, then faced similar issues when tirz was also removed from shortage

What to do in 2026

If you need GLP-1 therapy now:

1. Try to get insurance coverage for branded products. Talk to your insurer. Use manufacturer savings cards.
2. Use manufacturer patient assistance programs. Novo Nordisk and Lilly both have programs that can meaningfully reduce cost for qualifying patients.
3. Consider alternatives. Branded liraglutide (Saxenda, Victoza) is now off-patent and generic. Less effective but cheaper.
4. Wait for orforglipron. Expected FDA approval mid-2026. Oral, small-molecule, potentially cheaper.
5. Wait for CagriSema and retatrutide. Further out but offer different price points when available.

What NOT to do:

The broader lesson

The compounded GLP-1 era illustrated both the strengths and weaknesses of the US pharmacy compounding system:

Strengths:

• Provided millions of patients access to revolutionary medications at accessible prices
• Responded to legitimate shortages quickly
• Generated competitive pressure that may have influenced pricing

Weaknesses:

• Quality control varied dramatically across compounders
• FDA enforcement was slow and inconsistent
• Legal gray zones encouraged aggressive marketing
• Some compounded products failed identity or potency testing

The outcome is a mixed picture. Many patients benefited. Some were harmed by substandard products. The regulatory response has been reasonable but not elegant.

What's coming

Orforglipron (2026) — oral GLP-1, potentially much lower manufacturing cost. Could fundamentally change access economics.

Retatrutide (2027) — stronger, probably more expensive initially, but competitive pressure may emerge.

Generic semaglutide (est. 2032+) — Novo Nordisk's patents extend significantly. True generic competition is years away.

Policy changes — Several state and federal initiatives aim to expand access. Outcomes uncertain.